ICA-27243 是一种选择性，有效和口服活性的 KCNQ2/Q3 钾通道开放剂，EC₅₀ 为 0.38 μM。ICA-27243 在激活 KCNQ4 和 KCNQ3/Q5 方面效果较差。ICA-27243 具有抗癫痫和抗惊厥作用。

ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC 50 of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects.

Solid

EC50: 0.38 μM (KCNQ2/Q3 potassium channel)

In SH-SY5Y human neuroblastoma cells, ICA-27243 produces membrane potential hyperpolarization that could be prevented by coadministration with the M-current inhibitors XE-991 and Linopirdine. ICA-27243 enhances both Rb efflux (EC50 = 0.2 μM) and whole-cell currents in Chinese hamster ovary cells stably expressing heteromultimeric KCNQ2/Q3 channels (EC50 = 0.4 μM). Activation of KCNQ2/Q3 channels is associated with a hyperpolarizing shift of the voltage dependence of channel activation (V1/2 shift of -19 mV at 10 μM). has not independently confirmed the accuracy of these methods. They are for reference only.

ICA-27243 (1-100 mg/kg; oral administration; male CD-1 mice) has anticonvulsant activity (ED 50 of 8.4 mg/kg) in the mouse maximal electroshock epilepsy model. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Wickenden AD, et al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol. 2008 Mar;73(3):977-86.
[2]. Amato G, et al. N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. ACS Med Chem Lett. 2011 Mar 31;2(6):481-4.

In Vitro: DMSO : 250 mg/mL (930.58 mM; Need ultrasonic)配制储备液